ZYUS Life Sciences (TSE:ZYUS) has released an update.
ZYUS Life Sciences, a Canadian life sciences company, has secured a pivotal Cannabis Drug License from Health Canada, enabling the firm to manufacture cannabis-containing drugs for clinical trials. The license will facilitate the upcoming Phase 2 Clinical Trial of Trichomylin® softgel capsules for cancer-related pain management. Additionally, ZYUS strengthens its intellectual property portfolio with a new South African patent for another drug candidate, reflecting its commitment to innovating pain management solutions.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
